Raj Chovatiya, MD, PhD, Director of the Center for Eczema and Itch at the Department of Dermatology at Northwestern University Feinberg School of Medicine, discusses the newly available JAK inhibitors for use in a variety of dermatological conditions. Dr. Chovatiya reviews how JAK inhibitors work differently from other agents to reduce inflammation and the benefits that they can have for certain patient populations.
Read More
Experts in the field discuss new therapies and how they will impact the dermatologist's practice.
Peter Lio, MD: Innovations in JAK Inhibitors
April 12, 2022
Peter Lio, MD, of Medical Dermatology Associates of Chicago in Chicago, Illinois, discusses recent innovations in atopic dermatitis therapies with regard to JAK inhibitors. Dr. Lio discusses several new drugs in this class, including topical ruxolitinib, oral abrocitinib, and oral upadacitinib, and provides important guidance for practitioners treating their patients with these new therapies.
MORE EXPERT PERSPECTIVES
Seemal Desai, MD, FAAD: The Newest JAK Inhibitors for Inflammatory Skin Diseases
Seemai Desai, MD, FAAD, a dermatologist in private and academic practice in Dallas, Texas, discusses the development and use of JAK inhibitors for inflammatory skin diseases, such as atopic dermatitis, and reviews the newly approved oral and topical JAK inhibitors for AD. Dr. Desai goes on to discuss the benefits he's observed when treating his patients with these new agents.
Read More